Osteosarcoma
"Osteosarcoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)
Descriptor ID |
D012516
|
MeSH Number(s) |
C04.557.450.565.575.650 C04.557.450.795.620
|
Concept/Terms |
Osteosarcoma- Osteosarcoma
- Osteosarcomas
- Osteosarcoma Tumor
- Osteosarcoma Tumors
- Tumor, Osteosarcoma
- Tumors, Osteosarcoma
- Sarcoma, Osteogenic
- Osteogenic Sarcomas
- Sarcomas, Osteogenic
- Osteogenic Sarcoma
|
Below are MeSH descriptors whose meaning is more general than "Osteosarcoma".
Below are MeSH descriptors whose meaning is more specific than "Osteosarcoma".
This graph shows the total number of publications written about "Osteosarcoma" by people in this website by year, and whether "Osteosarcoma" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 0 | 1 | 1 | 1996 | 1 | 0 | 1 | 1998 | 0 | 1 | 1 | 2001 | 1 | 0 | 1 | 2003 | 1 | 0 | 1 | 2004 | 1 | 0 | 1 | 2005 | 1 | 0 | 1 | 2006 | 2 | 0 | 2 | 2007 | 1 | 0 | 1 | 2008 | 2 | 0 | 2 | 2009 | 3 | 0 | 3 | 2010 | 4 | 0 | 4 | 2011 | 2 | 0 | 2 | 2012 | 2 | 1 | 3 | 2013 | 3 | 0 | 3 | 2014 | 3 | 2 | 5 | 2015 | 5 | 1 | 6 | 2016 | 3 | 0 | 3 | 2017 | 3 | 1 | 4 | 2018 | 1 | 1 | 2 | 2019 | 2 | 1 | 3 | 2020 | 0 | 1 | 1 | 2021 | 2 | 0 | 2 | 2022 | 1 | 0 | 1 | 2023 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Osteosarcoma" by people in Profiles.
-
Weiser DA, Hayashi M, Applebaum MA. Breaking Up Isn't Hard to Do: Isolating Cell-free DNA Fragments in Osteosarcoma. Clin Cancer Res. 2023 06 01; 29(11):2017-2019.
-
Marinoff AE, Spurr LF, Fong C, Li YY, Forrest SJ, Ward A, Doan D, Corson L, Mauguen A, Pinto N, Maese L, Colace S, Macy ME, Kim A, Sabnis AJ, Applebaum MA, Laetsch TW, Glade-Bender J, Weiser DA, Anderson M, Crompton BD, Meyers P, Zehir A, MacConaill L, Lindeman N, Nowak JA, Ladanyi M, Church AJ, Cherniack AD, Shukla N, Janeway KA. Clinical Targeted Next-Generation Panel Sequencing Reveals MYC Amplification Is a Poor Prognostic Factor in Osteosarcoma. JCO Precis Oncol. 2023 03; 7:e2200334.
-
Toland AMS, Lam SW, Varma S, Wang A, Howitt BE, Kunder CA, Kerr DA, Szuhai K, Bov?e JVMG, Charville GW. GRM1 Immunohistochemistry Distinguishes Chondromyxoid Fibroma From its Histologic Mimics. Am J Surg Pathol. 2022 10 01; 46(10):1407-1414.
-
Self C, MacQuarrie KL, Cost CR. Osteosarcoma/Ewing Sarcoma. Pediatr Rev. 2022 05 01; 43(5):256-265.
-
Pin F, Prideaux M, Bonewald LF, Bonetto A. Osteocytes and Cancer. Curr Osteoporos Rep. 2021 12; 19(6):616-625.
-
Ingley KM, Maleddu A, Grange FL, Gerrand C, Bleyer A, Yasmin E, Whelan J, Strauss SJ. Current approaches to management of bone sarcoma in adolescent and young adult patients. Pediatr Blood Cancer. 2022 02; 69(2):e29442.
-
Mirabello L, Zhu B, Koster R, Karlins E, Dean M, Yeager M, Gianferante M, Spector LG, Morton LM, Karyadi D, Robison LL, Armstrong GT, Bhatia S, Song L, Pankratz N, Pinheiro M, Gastier-Foster JM, Gorlick R, de Toledo SRC, Petrilli AS, Patino-Garcia A, Lecanda F, Gutierrez-Jimeno M, Serra M, Hattinger C, Picci P, Scotlandi K, Flanagan AM, Tirabosco R, Amary MF, Kurucu N, Ilhan IE, Ballinger ML, Thomas DM, Barkauskas DA, Mejia-Baltodano G, Valverde P, Hicks BD, Zhu B, Wang M, Hutchinson AA, Tucker M, Sampson J, Landi MT, Freedman ND, Gapstur S, Carter B, Hoover RN, Chanock SJ, Savage SA. Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in Patients With Osteosarcoma. JAMA Oncol. 2020 05 01; 6(5):724-734.
-
Reed DR, Metts J, Pressley M, Fridley BL, Hayashi M, Isakoff MS, Loeb DM, Makanji R, Roberts RD, Trucco M, Wagner LM, Alexandrow MG, Gatenby RA, Brown JS. An evolutionary framework for treating pediatric sarcomas. Cancer. 2020 06 01; 126(11):2577-2587.
-
Rokita JL, Rathi KS, Cardenas MF, Upton KA, Jayaseelan J, Cross KL, Pfeil J, Egolf LE, Way GP, Farrel A, Kendsersky NM, Patel K, Gaonkar KS, Modi A, Berko ER, Lopez G, Vaksman Z, Mayoh C, Nance J, McCoy K, Haber M, Evans K, McCalmont H, Bendak K, B?hm JW, Marshall GM, Tyrrell V, Kalletla K, Braun FK, Qi L, Du Y, Zhang H, Lindsay HB, Zhao S, Shu J, Baxter P, Morton C, Kurmashev D, Zheng S, Chen Y, Bowen J, Bryan AC, Leraas KM, Coppens SE, Doddapaneni H, Momin Z, Zhang W, Sacks GI, Hart LS, Krytska K, Mosse YP, Gatto GJ, Sanchez Y, Greene CS, Diskin SJ, Vaske OM, Haussler D, Gastier-Foster JM, Kolb EA, Gorlick R, Li XN, Reynolds CP, Kurmasheva RT, Houghton PJ, Smith MA, Lock RB, Raman P, Wheeler DA, Maris JM. Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design. Cell Rep. 2019 11 05; 29(6):1675-1689.e9.
-
Kopp LM, Malempati S, Krailo M, Gao Y, Buxton A, Weigel BJ, Hawthorne T, Crowley E, Moscow JA, Reid JM, Villalobos V, Randall RL, Gorlick R, Janeway KA. Phase II trial of the glycoprotein non-metastatic B-targeted antibody-drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: A report from the Children's Oncology Group. Eur J Cancer. 2019 11; 121:177-183.
|
People ![Expand Description](https://profiles.ucdenver.edu/Framework/Images/info.png) People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|